| Title |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2010
|
| DOI | 10.1007/s00280-010-1282-4 |
| Pubmed ID | |
| Authors |
Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, Laetitia Dahan, Danielle Bagarry-Liegey, Caroline Brunet, Arthur Varoquaux, Nicolas Frances, Hafedh Marouani, Antoine Giovanni, Rose-Marie Ferri-Dessens, Mohamed Chefrour, Roger Favre, Florence Duffaud, Jean-François Seitz, Michel Zanaret, Bruno Lacarelle, Cédric Mercier |
| Abstract |
Fluoropyrimidine drugs are widely used in head and neck cancer (HNC). DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake. We have developed a simple, rapid, and inexpensive functional testing for DPD activity, as a means to identify deficient patients and to anticipate subsequent 5-FU-related toxicities. We present here the impact of fluoropyrimidine dose tailoring based on DPD functional screening in a prospective, open, non-controlled study, both in term of reduction in severe toxicities and of treatment efficacy. |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | 3% |
| Japan | 1 | 1% |
| China | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 75 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 15% |
| Student > Ph. D. Student | 10 | 13% |
| Researcher | 9 | 11% |
| Other | 9 | 11% |
| Professor | 7 | 9% |
| Other | 19 | 24% |
| Unknown | 14 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 40% |
| Agricultural and Biological Sciences | 13 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 13% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Mathematics | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 14 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2019.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#35,614
of 95,676 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#10
of 23 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,676 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.